Exhibit 99.1 Contact: Kathleen Nemeth Omnicell, Inc. Senior Vice President, Investor Relations 4220 North Freeway 650-435-3318 Fort Worth, TX 76137 Kathleen.Nemeth@Omnicell.com Omnicell Announces Second Quarter 2024 Results Results exceed previously issued second quarter guidance across all metrics Total revenues of $277 million GAAP net income per diluted share of $0.08 Non-GAAP net income per diluted share of $0.51 Raises 2024 non-GAAP EBITDA and non-GAAP earnings per share guidance FORT WORTH, Texas -- A ...

Does Earnings Surprise History Hold Any Clue? While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that Omnicell would post a loss of $0.08 per share when it actually produced earnings of $0.03, delivering a surprise of +137.50%. Over the last four quarters, the ...

The renowned healthcare technology company has a market capitalization of $1.36 billion. Omnicell surpassed estimates in each of the trailing four quarters, delivering an average negative earnings surprise of 93.2%. Image Source: Zacks Investment Research Macro Concerns Put Pressure on the Bottom Line: Myriad Genetics has been grappling with escalated expenses for a while. Deteriorating international trade, global inflationary pressure leading to a tough situation Estimate Trend Some better-ranked stocks in ...

Omnicell (OMCL) has been gaining from the successful execution of its growth strategies. Yet, macroeconomic concerns continue to impede growth. The stock carries a Zacks Rank #3 (Hold) currently. Omnicell strategizes to offer differentiated, innovative solutions, expand into new markets and grow through strategic partnerships and acquisition of new technologies. The company successfully increased its installed base of Point of Care connected devices through market share gains in the past three years. In 202 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 OMNI ...

Omnicell, Inc. (OMCL) reported first-quarter 2024 adjusted earnings per share (EPS) of 3 cents compared with 39 cents in the year-ago quarter. However, the metric beat the Zacks Consensus Estimate of a loss of 8 cents per share.Adjustments include one-time expenses like share-based compensations, the amortization of acquired intangibles, acquisition-related expenses, executive transition costs, severance-related expenses and others.GAAP loss was 34 cents per share in the quarter under review compared with 3 ...

Omnicell, Inc. (NASDAQ:OMCL) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Kathleen Nemeth – Senior Vice President-Investor Relations Randall Lipps – Founder, Chairman, President and Chief Executive Officer Nchacha Etta – Executive Vice President and Chief Financial Officer Conference Call Participants Stan Berenshteyn – Wells Fargo Matt Hewitt – Craig-Hallum Scott Schoenhaus – KeyBanc Jessica Tassan – Piper Sandler Jenny Shen – BTIG Anna Kruszenski – Barclays Bill Sutherland ...

May 2, 2024 This presentation contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles ("GAAP"), including Q1-2024 non-GAAP gross margin, non-GAAP operating expense, nonGAAP EBITDA, and non-GAAP earnings per share, 2017 and Q1-2024 liquidity and 2017 and Q1-2024 net debt/EBITDA, guidance with respect to 2024 non-GAAP EBITDA and non-GAAP earnings per share. Reconciliations of the 2017 and Q1-2024 non-GAAP financial measures to the most directly comp ...

Omnicell (OMCL) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to earnings of $0.39 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 137.50%. A quarter ago, it was expected that this Omnicell Inc. Would post earnings of $0.17 per share when it actually produced earnings of $0.33, delivering a surprise of 94.12%.Over the last four quarters, th ...

Exhibit 99.1 Contact: Kathleen Nemeth Omnicell, Inc. Senior Vice President, Investor Relations 4220 North Freeway 650-435-3318 Fort Worth, TX 76137 Kathleen.Nemeth@Omnicell.com Omnicell Announces First Quarter 2024 Results Results exceed prior first quarter guidance across all metrics Total GAAP revenues of $246 million FORT WORTH, Texas -- May 2, 2024 -- Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy care delivery model, t ...